The 2014 VA/DoD HTN CPG recommended treatment to an SBP of <150 mm Hg in patients 60 years and over with type 2 diabetes, primarily based on the results of general HTN studies which had sub- populations with diabetes [64,65] and the HTN arm of the UK Prospective Diabetes Study Group.[66] In the 2014 VA/DoD HTN CPG, there was an additional suggestion to treat to an SBP of <140 mm Hg for those patients who tolerate pharmacologic antihypertensive treatment based on evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trials;[67,68] however, this evidence was only moderate, which led to the Weak for recommendation in 2014. The SR by Brunstr m et al. (2017) strengthened the evidence providing support for the amended Strong for recommendation to treat to target SBP of <140 mm Hg and to consider additional blood pressure lowering when the SBP is between The patient focus group revealed that some patients do not want to take medications for treatment of HTN. This may limit the ability to achieve target SBP. As this is a Reviewed, Amended recommendation, the Work Group systematically reviewed evidence related to this recommendation identified in the evidence review conducted as part of this guideline update,[54,59] as well as considered evidence from the 2014 VA/DoD HTN CPG.[64-68] The Work Group determined the confidence in the quality of the evidence was high in support of intensive treatment of HTN in a general population of patients with diabetes. 